The intravenous sensitization of C57BL/6 (B6) mice with class I H-2-disparate B6-C-H-26'°1 (bml) spleen cells resulted in the abrogation of CD8+ T cell-mediated anti-bml (proliferative and interleukin 2-producing) T helper (Th) cell activities. In vitro stimulation of lymphoid cells from these mice with bml cells, however, generated a reduced, but appreciable, anti-bml cytotoxic T lymphocyte (CTL) response. Moreover, the anti-bml CTL response, upon stimulation with [bml x B6-C-H-26 -12 (bm12)]F1 spleen cells, was enhanced when compared with the response induced upon stimulation with bml cells. These in vitro results were reflected on in vivo graft rejection responses; bml skin grafts engrafted in the bml-presensitized B6 mice exhibited prolonged survival, whereas (bml x bm12)F1 grafts placed collateral to bml grafts (dual engrafted mice) inhibited the tolerance to bml . In the B6 mice 1-2 d after rejecting the bml grafts, anti-bml Th activities remained marginal, whereas potent anti-bml CTL responses were found to be generated from their spleen cells . Administration in vivo of anti-CD4 antibody into bml-presensitized, dual graft-engrafted mice prolonged bml graft survival and interfered with enhanced induction of anti-bml CTL activity. These results indicate that anti-class I alloantigen (bml) tolerance as induced by intravenous presensitization with the relevant antigens is not ascribed to the elimination of CD8+ CTL precursors, but to the specific inactivation of CD8+ Th cells, whose function can be bypassed by activating third-party Th cells. (4) showed that allograft rejection results from interactions especially between T cells ofdifferent phenotypes, or of different antigen specificities, and with distinct functions . It would be of importance to consider this when an immune manipulation is attempted to induce the tolerance of anti-allo-immune responses.
Summary
The intravenous sensitization of C57BL/6 (B6) mice with class I H-2-disparate B6-C-H-26'°1 (bml) spleen cells resulted in the abrogation of CD8+ T cell-mediated anti-bml (proliferative and interleukin 2-producing) T helper (Th) cell activities. In vitro stimulation of lymphoid cells from these mice with bml cells, however, generated a reduced, but appreciable, anti-bml cytotoxic T lymphocyte (CTL) response. Moreover, the anti-bml CTL response, upon stimulation with [bml x B6-C-H-26 -12 (bm12)]F1 spleen cells, was enhanced when compared with the response induced upon stimulation with bml cells. These in vitro results were reflected on in vivo graft rejection responses; bml skin grafts engrafted in the bml-presensitized B6 mice exhibited prolonged survival, whereas (bml x bm12)F1 grafts placed collateral to bml grafts (dual engrafted mice) inhibited the tolerance to bml . In the B6 mice 1-2 d after rejecting the bml grafts, anti-bml Th activities remained marginal, whereas potent anti-bml CTL responses were found to be generated from their spleen cells . Administration in vivo of anti-CD4 antibody into bml-presensitized, dual graft-engrafted mice prolonged bml graft survival and interfered with enhanced induction of anti-bml CTL activity. These results indicate that anti-class I alloantigen (bml) tolerance as induced by intravenous presensitization with the relevant antigens is not ascribed to the elimination of CD8+ CTL precursors, but to the specific inactivation of CD8+ Th cells, whose function can be bypassed by activating third-party Th cells. 4) showed that allograft rejection results from interactions especially between T cells ofdifferent phenotypes, or of different antigen specificities, and with distinct functions . It would be of importance to consider this when an immune manipulation is attempted to induce the tolerance of anti-allo-immune responses.
The presentation of alloantigens via an intravenous route regulates positively or negatively the induction of anti-alloimmune responses, as has been reported for the effect ofdonorspecific transfusion (DST)' (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . Earlier studies from our 1 Abbreviations used in this paper . DST, donor-specific transfusion ; FMF, flow microfluorometry; MLR, mixed lymphocyte reaction ; SN, supernatant . laboratory have demonstrated that anti-allo-H-2 antigen tolerance, which leads to prolonged graft survival, is inducible by intravenous presensitization with cells expressing the corresponding allo-H-2 antigens (16) (17) (18) . This was, however, achieved in two simplified donor-host combinations with either class I (16, 17) or class II (18) H-2 disparity. Since engrafting allogeneic tissue with complex disparity induces rejection responses involving complicated cellular interactions, it will be required to investigate how an anti-allo T cell response is influenced by other T cell responses. Such an investigation could contribute to initiating the establishment of anti-allo-tolerance in the donor-host combinations with a complex disparity.
The present study was undertaken to investigate how antiallo-class I H-2 tolerance is influenced when third-party Th function is introduced by engrafting a class I and class II H-2-disparate graft. The results demonstrate that intravenous presensitization ofB6 mice with bml cells induced the abrogation of anti-bml Th activity and the prolongation ofbml skin graft survival. However, when bml-presensitized B6 mice were engrafted with a (bml x bm12)F1 skin graft collateral to a bm1 skin graft, the bml graft was rejected along with the (bml x bm12)Ft graft without exhibiting its prolonged survival . It is also shown that unprolongation of bml graft survival in bml-presensitized B6 mice engrafted with dual skin grafts is associated with enhanced generation of antibml CTL activity, and prevented by in vivo injection of anti-CD4 antibody.
Materials and Methods
Mice. C57BL/6 (B6) and BALB/c mice were purchased from Shizuoka Experimental Animal Laboratory. B6-C-H-211'"1 (bml) and B6-C-H-26°' 12 (bm12) mice were originally provided by D.H. Sachs (NationalCancer Institute, Bethesda, MD). These two strains of mutant mice and their hybrid (bml x bm12)F 1 mice were bred by mating in our laboratory. These mice were used for experiments at 7-9 wk of age. Female mice were used throughout this study except for donor mice of grafts in some experiments .
Intravenous Presensitization with Allogeneic Cells. Mice were injected with 10' allogeneic bml spleen cells intravenously.
Media Used for In Vitro Cell Culturing. Culture medium used for the mixed lymphocyte reaction (MLR) was RPMI 1640 supplemented with 10% horse serum, 5 x 10-5 M 2-ME, sodium pyruvate, glutamine, nonessential amino acids, and 5 mM hepes buffer. Complete medium for the generation of CTL was prepared by replacing 10% horse serum with 10% FCS in the above medium. RPMI 1640 supplemented with 5% FCS plus 5 x 10 -5 M 2-ME was used for the production of IL2 and IL2 assays.
mAbs. Anti-L3T4 (GK1.5) (19) and anti-Lyt-2 (3 .155) (American Type Culture Collection, Rockville, MD) mAbs were obtained from culture supernatants of hybridomas producing the relevant antibody. GK1.5 mAb was also obtained in a form of ascitic fluid. Gamma globulin fraction of the ascitic fluid was obtained by precipitation at 50% saturation with ammonium sulfate and used for in vivo administration .
Treatment of Lymphoid Cells with Antibody Plus Complement (C). Spleen or lymph node cells (108) were incubated at 4°C for 30 min with appropriate dilutions of anti-L3T4 or -Lyt-2 mAb. Cells were washed and incubated at 37°C for 45 min with rabbit C preabsorbed with syngeneic mouse spleen cells at a final dilution of 1 :20. The efficacy of these antibody treatments was confirmed in flow microfluorometric analysis by demonstrating that the treatment with anti-L3T4 or -Lyt-2 antibody results in almost complete elimination of the respective Lyt-2' (CD8+) or L3T4* (CD4+) T cell subset without damage onto the other alternative T cell subset .
MLR . The responding lymph node or spleen cells, obtained from a pool of three to five animals per group, were resuspended in complete medium and cultured at a concentration of 2 x 105 cells per culture well together with 4 x 105 irradiated (2,000 rad) stimulating spleen cells in a total volume of 0.2 ml (16) (17) (18) . Each MLR was performed in triplicate in flat-bottomed microculture plates (25860 ; Corning Glass Works, Coming, NY) and maintained in a humidified atmosphere at 5% C02 at 37°C . The cultures were harvested at 96 h after an 8-h pulse with 20 KBq/well of [3H]TdR by using an automatic cell harvester onto glass fiber filters. Radioactivity was determined by liquid scintillation spectrometry. Results were calculated from uptake of [3H]TdR and expressed as the mean uptake in cpm ± SE of triplicate cultures .
Generation of CTL. The CTL induction in macrocultures was performed as previously described (20) . Briefly, 5 x 106 lymph node or spleen cells were cultured in vitro with 106 irradiated
106
Graft Rejection by Cell-Cell Interaction (2,000 rad) syngeneic or allogeneic spleen cells in 24-well culture plates (25820 ; Corning Glass Works) in a volume of 2 ml at 37°C for 5 d. Effector cells generated were assayed on 51 Cr-labeled target cells (spleen cells cultured for 48 h with Con A, 5 ttg/ml). Percent specific lysis was calculated as described (20) . SEs in each group were < 10%, and these were excluded from the figures for simplicity.
To detect limiting effects of CTL precursors, CTL induction was performed in some experiments according to limiting dilution assay as described (17) . Briefly, graded numbers of lymph node cells were cultured with 105 x-irradiated stimulating spleen cells in 96-well microplates in the absence of exogenous 1162, and 5 d later, "Crlabeled Con A blast target cells (10°) were directly added to each culture well (six wells/group). Production of IL2 and Assay System for IL2 Activity. A mixture of lymph node and spleen cells (5 x 106) was cultured with 3 x 106 syngeneic or allogeneic stimulator spleen cells (2,000 rad) in 24-well culture plates (25820 ; Corning Glass Works) in a volume of 1 ml (16) (17) (18) . After incubation at 37°C in a humidified incubator (5% C02) for 48 h, culture supernatants (SN) were harvested by centrifugation and stored at -20°C until use.
SN were assayed for IL2 activity according to their ability to support the proliferation of the IL2-dependent T cell line CTLIr2 (16) (17) (18) . CTLL2 (10'/well) were cultured with the supernatant in a volume of 0.2 ml in 96-well flat-bottomed microplates (25860; Corning Glass Works) for 24 h at 37°C. Proliferation was assessed by the uptake of [3H]TdR during a 4-h pulsing with 20 KBq
FITC-conjugated Antibodies. FITC was conjugated to GK1.5 mAb by regular methods, followed by DE-52 (Whatman Biochemicals Ltd., England) ion exchange chromatography (21) . The F/P ratio of FITC/GK1 .5 was 1.6 . FITC-conjugated anti-Lyt-2 and mouse anti-rat Ig antibodies were the products of Becton Dickinson Immunocytometry Systems, Mountain View, CA .
Immunofluorescence Staining and Flow Microfluorometry (FMF) .
The cell preparation and staining procedures were essentially the same as described previously (22) . Briefly, 106 lymphoid cells were incubated at 4°C for 30 min with FITC-conjugated antibodies, washed twice, resuspended, and analyzed for fluorescence. These procedures were performed in HBSS (without phenol red) containing 0.1% BSA and 0.1% sodium azide. FMF analysis was performed by using a FACStar (Becton Dickinson Immunocytometry Systems) . All data were collected by using log amplification, and dead cells were rejected from analysis by additional staining with propidium iodide.
Skin Grafting of B6 Mice. B6 mice were engrafted on the flank with two tail skin grafts, separated by a host skin bridge, according to an adaptation of the method of Billingham and Medawar (23) . Bandages were removed on day 7, and the grafts were scored daily until rejection (defined as loss of > 80% of the grafted tissue).
Results
Responses of Lymphoid Cells from bml presensitized B6 Mice to bml Alloantigens upon the Stimulation with (bml x bm12)Fl Cells. B6 mice were injected intravenously with 107 bml spleen cells. 1 wk later, lymph node cells were obtained from thesebml-presensitized or -unpresensitized B6 mice and treated with anti-CD4 (GK1 .5) or anti-CD8 (3 .155) mAb plus C. The resultant cells (CD8+ or CD4 subset of T cells) or unfractionated cells were stimulated in vitro with irradiated bml or (bml x bm12) cells. The results of Tables 1 and 2 confirm the fact (16, 17) that intravenous presensitization of B6 mice B6 mice were injected intravenously with 107 bml spleen cells. t Lymph node cells 1 wk after the bml presensitization were treated with anti-CD4 (GK1 .5) or anti-CD8 (3 .155) antibody plus C. 5 Lymph node cells (2 x 10 5/well) were cultured with 2,000-rad X-irradiated spleen cells (4 x 105/well) from the indicated strains of mice for 4 d.
with bml alloantigens resulted in almost complete abrogation of CD8+ T cell-mediated anti-bml proliferative (Table  1) and IIr2-producing (Table 2) capacities . It is also shown that since the presensitization with bml cells did not affect the responsiveness of CD4+ T cell subset, this subset of T cells exhibited comparable magnitudes ofanti-bm12 responses upon the stimulation with (bml x bml2)Ft cells in both MLR and ID2 production.
Earlier studies from our laboratory have also demonstrated that intravenous presensitization with bml cells failed to abrogate CD8+ T cell-mediated anti-bml CTL responses in contrast to the elimination of CD8+ Th (proliferative and 11,2-producing) capacities (16, 17) . The results of Table 1 . t Responding cells (5 x 106/well) were cultured with 2,000-rad X-irradiated spleen cells (3 x 106/well) from the indicated strains of mice for 2 d. Culture supernatants were submitted to IL-2 assay using CTLL-2 cells. 
CD4+ T cells from responding cells before CTL induction.
These results suggest that the anti-bml CTL responses of cells from the bml-presensitized B6 mice are reduced due to elimination of anti-bml CD8+ Th cells, but these responses may be augmented by introduction of an alternative CD4+ Th mechanism (anti-bm12 Th). Anti-brnl Graft-rejecting Capacity Reduced by Intravenous Presensitization Is Recovered by Engrafting (bm1 x bm12)F) Collateral Grafts. B6 mice were presensitized intravenously with bml cells, and 1 wk later, these bml-presensitized mice were engrafted with a bml graft (detecting graft) on the right flank along with a collateral graft [bm12 or (bml x bm12)F)] on the left flank. The results of Fig. 2 illustrate that (a) intravenous presensitization o£ B6 mice with bml cells results in the prolonged survival of bml skin grafts, which confirms the previous report (17) ; and (b) such prolongation of bml graft survival is prevented when B6 recipients are engrafted with a (bml x bml2)Fi skin graft as a collateral graft. It should be noted that engrafting bm12 skin grafts did not prevent the prolongation of the bm1 skin graft survival, which is induced by intravenous presensitization with bml cells.
Analysis of Anti-61 T Cell Responses in bm1 presensitized B6 Mice after (bml x bm12)Fl Skin Grafting. To determine cellular mechanisms by which the prolongation ofbml skin graft survival in bml-presensitized B6 mice is prevented by engrafting (bml x bm12)Fl collateral grafts, we examined anti-bml Th (proliferative and IL2-producing) (Tables 3 and  4) , as well as CTL, activities (Fig. 3) only weak anti-bml proliferative (Table 3) and only marginal 11,2-producing (Table 4) activities. These results indicate that potent anti-bml suppressive state is still maintained at the CD8+ Th level, even after the dual skin-grafting. Fig. 3 shows the generation ofCTL activityby spleen cells obtained from the same mice as used in Tables 3 and 4 . Appreciable levels of anti-bml CTL responses generated in B6 mice receiving only bml presensitization regimen were attenuated after bml skin grafting (Fig. 3) , which is consistent with the previous results (17) . Such a reduced anti-bml CTL potential was also observed in bml-presensitized B6 mice that were engrafted with a bm12 collateral skin graft (Fig. 3) . However, when bml-presensitized mice were engrafted with a (bml x bm12)Fl graft as a collateral graft along with a bml skin graft, spleen cells from these mice (10 d after the dual skin grafting) produced potent anti-bml CTL activity. Such an activity was comparable with or slightly higher than that observed in unpresensitized normal B6 mice. These results indicate that anti-bml CTL potential in bml-presensitized mice, which is otherwise attenuated by bml skin grafting, can be induced for its enhanced activation when the recipient mice are engrafted with (bml x bm12)Fi collateral grafts.
Re irement ofCD4+ T Subsetfor Preventing the Prolongation ofbm1 Skin Graft Survival in bmi presensitized, Dual Skinengrafted B6 Mice We next investigated whether CD4+ T cells reactive with bm12 alloantigens are involved in the prevention of prolonged bml graft survival in bml-presensitized mice receiving a collateral (bml x bm12)F1 graft. Semipurified anti-CD4 (GK1.5) antibody was administered in vivo at the dose of 100 wg/d, three times/wk to eliminate CD4+ T cells. This procedure was continued for 1-8 wk, and at each stage, the efficacy of the procedure to deplete CD4+ T cells was examined. Intraperitoneal injection ofanti-CD4 an- Table 3 . Anti-61proliferating T Cell Activity in bmlpresensitized B6 Mice 10 d after Dual Skin Grafting ' bml-presensitized B6 mice were engrafted with a bml-detecting graft and the indicated collateral graft. t 10 d after the dual skin grafting, lymph node cells were harvested and stimulated with spleen cells (shown) in MLR.
tibody for 1 wk (three times) induced the depletion of > 90% CD4+ T cells (data not shown) . Administration of the antibody for an additional week (2 wk, six times) resulted in almost complete elimination of CD4+ T cells without affecting the CD8+ T cell subset (Fig . 4) . The CD4+ T cell-depleted state was maintained by continued administration of the anti-CD4 antibody for 8 wk (data not shown) . bml-presensitized B6 mice were engrafted with bml and bm12 or (bml x bml2)Ft collateral skin grafts, and the Table 4 . Anti-bml IL-2-producing T Cell Activity in bm1presensitized B6 Mice 10 d after Dual Skin Grafting " Responding spleen cells were obtained from the same donor mice as used in Table 3 . 109 Kitagawa et al.
above protocol of anti-CD4 antibody administration was started on the same day as the dual skin grafting (Fig . 5) .
The results illustrate that in vivo administration of anti-CD4 antibody resulted in an appreciable prolongation of bml skin graft survival under conditions in which bml-presensitized B6 mice were engrafted with bml and (bml x bml2)Ft skin grafts . These results indicate that the CD4+ T cell subset is responsible for preventing the prolongation of bml graft survival in the dual grafting model. Additional experiments were performed to investigate whether the in vivo effect of anti-CD4 antibody administration is related to the suppression of anti-bml CTL generation . bml-presensitized B6 mice were engrafted with two skin grafts [bml and (bml x bm12)Ft], and the administration of anti-CD4 antibody was started simultaneously with the dual skin grafting . 10 d after the dual skin grafting, spleen cells from these antibody-treated or untreated mice were tested for their ability to generate anti-bml CTL responses . The results of . Effect of (bml x bml2)Fl skin grafting is prevented by in vivo administration of anti-CD4 antibody. B6 mice were unpresensitized or presensitized with bml cells and engrafted with two skin grafts as indicated. The injection of anti-CD4 antibody (100 pg/day, three times/wk) was started on the same day as the dual skin grafting .
anti-CD4 antibody prevents the generation ofanti-bm1 CTL responses that are otherwise induced by spleen cells from bmlpresensitized B6 mice after two skin [bml and (bml x bm12)F1] graftings. Taken collectively, these results indicate that elimination of the CD4+ T cell subset results in the prevention of the prolonged bml graft survival along with inhibition of the generation of anti-bml CTL responses.
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Effector. target ratio Anti-SALB/c Figure 6 . Suppression of anti-brat CTL generation in bmlpresensitized, dual skin-engrafted B6 mice by injection of anti-CD4 antibody. B6 mice were unpresensitized or presensitized with bml cells and engrafted with the indicated detecting and collateral grafts. The injection of anti-CD4 antibody was started on the same day as the dual skin grafting. Spleen cells from each group of mice were obtained 10 d later. 
Dare attar skin-grafting Figure 7 . Male bml collateral skin grafting induces the rejection of female bml grafts in bml-presensitized female mice. Unpresensitized or bml-presensitized female B6 mice were engrafted with the indicated collateral and detecting grafts.
Breakdown of Anti-bml CD8+ T Cell Tolerance by Introduction of anti-male Th Mechanism. We finally investigated whether breakdown of anti-bml CD8+ T cell tolerance by the introduction of an alternative Th mechanism can be generalized, i .e., breakdown of this tolerance is inducible by introducing on a collateral (sensitizing) graft other cell surface antigens than H-2 antigens. Female B6 mice were presensitized with female bml cells, as has been performed in the preceding experiments. These bml-presensitized and unpresensitized B6 mice were engrafted with one or two skin grafts that were of B6 or bml, and male or female. The results are summarized in Fig . 7 . The results demonstrate that (a) B6 male grafts were rejected in B6 female recipients although the rejection was significantly delayed compared with that of allogeneic bml (female) grafts ; (b) the survival of female bml-detecting grafts was prolonged in bml-presensitized mice. This was also the case when these recipient mice were engrafted with male B6 collateral grafts that themselves were rejected in comparable time courses with those observed for male B6-detecting grafts; (c) in contrast, engrafting male bmlcollateral grafts resulted in appreciably accelerated rejection of female bml-detecting grafts. These results indicate that (a) cell-cell interactions capable of mounting enhanced rejection responses are observed between T cells against various types of antigens ; and (b) coexpression of these antigens on a single graft is required for the induction of enhanced rejection responses .
A major issue in transplantation immunology is to analyze the mechanisms underlying cellular interactions involved in in vivo responses to alloantigens . It has been shown that allograft rejection results from interactions between Th and effector T cells (e.g., CTL) of different phenotypes and of different antigen specificities (4), although rejection of class 11 1 Kitagawa et al .
I H-2-disparate grafts can be mediated by isolated CD8+ T cell populations (24, 25) . Another important goal is the establishment o£ immune manipulations by which clonal elimination and/or functional inactivation of alloantigen-reactive T cells are achieved . One of immunobiological manipulations wouldbe to attempt negative regulation of immune responses by introduction of alloantigens via an intravenous route . This effect has been recognized as the beneficial one of pretransplant DST in clinical studies (5) (6) (7) (8) (9) (10) . We have also demonstrated in animals studies that CD8 + T cell responses to allo-class I H-2 or CD4+ T cell responses to allo-class II H-2 antigens can be tolerized by intravenous presensitization with cells expressing the corresponding alloantigens (16) (17) (18) . In considering that cellular interactions between phenotypically andfunctionally distinct subsets of T cells are involved in the rejection responses in general, it would also be important to investigate how each component of T cell responses is mutually influenced by other component(s) of these.
In the present study, we have investigated the effects of cellular interactions on the induction and/or maintenance of anti-allo-tolerance induced by the above-mentioned intravenous presensitization regimen. The results demonstrate that (a) intravenous presensitization of B6 mice with class I H-2-disparate bml cells results in the abrogation of CD8+ Th cell activity, leading to the prolongation of bml graft survival; (b) when bml-presensitized mice were engrafted with bml and (bml x bm12)Ft grafts, the survival of the bml graft was not prolonged, but this graft was rejected along with the (bml x bm12)F1 graft ; (c) only marginal or potent antibml CTL activity was generated by spleen cells from bmlpresensitized mice that were followed by engrafting only bml or two [bml and (bml x bm12)FiJ grafts, respectively; (d) the effect of engrafting collateral (bml x bm12)Ft grafts on the generation of CTL responses and inhibition of prolonged bml graft survival was abrogated by eliminating CD4+ T cells able to react with bm12 alloantigens and to exert an alternative (anti-bm12) Th activity ; and (e) a similar effect of cell-cell interaction to that observed between anti-bml (alloclass I H-2) and anti-bm12 (allo-class II H-2) T cells was also inducible by the interaction between anti-bml and anti-male (non-H-2) responses .
The intravenous presensitization with bml cells did not eliminate the total anti-bml CTL capacity. The reduced but appreciable frequencies of CTL precursors were detected in lymph node and spleen cells (17) . Such CTL potential remaining in the bml-presensitized mice was suppressed along with the engrafting ofbml skin grafts (17) . The present results that bml presensitized, two graft [bml and (bml x bm12)Ft]-engrafted mice were capable of developing enhanced anti-bml CTL responses indicated the involvement of anti-bm12 responses in the generation of potent anti-bml CTL responses . Thus, it is conceivable that CD4* T cellmediated anti-bm12 Th cell activity helped to activate antibml CTL precursors remaining in the bml-presensitized mice that are otherwise attenuated after the engrafting of bm1 grafts alone. It is also possible that such CTL activity contributed to the rejection in vivo ofbrnl grafts. The results that elimination of CD4+ T cells by administrating anti-CD4 antibody fails to generate these in vitro and in vivo effects could support the above postulation.
Cell-cell interactions similar to those observed here were originally reported by Rosenberg et al. (4) . In their model, CD4+ Th cells reactive to allo-class II H-2 generated help for the activation of anti-Kbm 6 or Qa1' CTL precursors that represent helper-dependent effectors and fail to mature without help from Th cells against other alloantigens . Thus, their observations and ours illustrate the role of CD4+ Th cells in positively regulating the activation of CTL responses to other alloantigens in various combinations .
The present study should be discussed from two distinct aspects . First, our results indicated that the activation ofantibm12 CD4+ Th cells is not sufficient for enhanced induction ofanti-bml CTL, as well as prevention of the prolonged bml graft survival, since the above in vitro and in vivo effects were induced when the recipient mice receiving bml grafts were engrafted with (bml x bm12)Fi but not with bm12 grafts as collateral ones. Thus, an appropriate microenvironment could be required under which the help of anti-bm12 CD4+ Th cells functions to efficiently activate anti-bml CTL precursors. It is conceivable that (bml x bm12)Ft cells expressing both bml and bm12 alloantigens are responsible for this cell-cell interaction process. It has been established that the stimulation of Th cells, especially priming of virgin Th cells, requires the participation ofAPC expressing helper determinants (1, 2) . Therefore, in this model, (bml x bml2)Ft cells that express helper (bm12) determinants and bml CTL antigens, and possess APC functions, i.e., Ia+ cells such as Langerhans cells, might be visualized as operating for the cellular interaction . It may also be possible that once anti-bm12 Th cells are activated to produce IFN-y capable of inducing the expression of la antigens on Ia cells (26) (27) (28) , skin cells rendered Ia+ by IFN-y (keratinocytes) might provide the function for stimulating both Th cells and CTL.
Another important aspect is concerned with the physiologic relevance of the present study. Since DST is attempted by using cells from the donor that provides the graft, the situation made in the present study, i.e., the activation of anti-class I CTL by anti-class II CD4+ Th cells, would be unrealistic. Nevertheless, it would be ofvalue to consider the clinical relevance of the present observations based on cellular interactions . Although only described for skin (29) , the existence of tissue-or organ-specific histocompatibility antigens has been suggested (30) . It could be that some of such tissue-or organ-specific histocompatibility antigens function as helper determinants, as has been observed for bm12 alloantigens. Thus, the existence of tissue-or organ-specific histocompatibility antigens is ofpractical importance when the induction ofdonor-specific tolerance attempts to use cells ofone tissue type, but organs ofanother tissue type are transplanted . The fact that the coexpression on a graft of malespecific antigen as a model of non-H-2 antigen induced enhanced rejection responses could support this notion .
The present results illustrate that the induction and/or maintenance of tolerance to a given alloantigen is influenced by cellular interactions between T cells against that antigen and other antigens coexpressed on a graft. Our recent study (Hori, S., S. Kitagawa, S. Sato, T Hamaoka, and H. Fujiwara, manuscript in preparation) also revealed that the effect of intravenous presensitization is modulated by cellular interactions between anti-class I and -class II H-2 T cells when class I-and class II-disparate cells are used for the intravenous presensitization. Taken together, these approaches could contribute to a better understanding of complex cellular interactions involved in graft rejection responses in vivo, and provide the validity for attempting to apply such studies to clinical transplantation immunology.
